An innovative new website is bringing fund managers and their research teams to the table-the operating table.

Sermo is giving buy-side firms a peek into the community website it runs for physicians, where they openly trade thoughts on medicine, devices and treatments.

Former surgery resident Daniel Palestrant started the Cambrige, Mass.-based company two years ago. "What is more powerful then a rush of information that you specifically asked for?" said Palestrant, Sermo chief executive officer.

Sermo's online community database has been likened to a MySpace for doctors. It allows any licensed doctor in the U.S. to join for free. Physicians can discuss healthcare issues, post questions and chat on any topic they wish. Healthcare is the largest industry in the nation, and thus far, 16,500 doctors have signed up for Sermo, out of 600,000 doctors in the U.S.

As more and more doctors are working in small two to three doctor offices, the appeal of Sermo is that it allows them to be part of a community and compare and share notes, Palestrant noted.

As Sermo is free, the way it makes money is by allowing investment firms access to the Sermo community of doctors. The company currently has 10 asset management clients, predominately hedge funds, which pay between $150,000 to $500,000 to subscribe each year.

Clients typically pay quarterly in soft-dollar arrangements, Palestrant said. The service costs a fraction of what it would cost to sign up for an expert matching service such as Gerson Lehrman, he said. A Gerson spokesperson was unavailable to comment before press time.

Gerson Lehrman is an independent research group that pairs experts with more than 400 clients in many different industries. Within the healthcare industry, the company offers GLG News, an online network of 70,000 physicians. Clients are also able to set up interviews with physicians to answer specific questions.

At Sermo, AlphaMD is the name of the front-end screen that clients use. There they can see what doctors are talking about and track specific companies that are of interest to them. Recent messages and the most active chats are also shown, so investors can figure out what is the latest hot topic in the healthcare community. Clients are able to tell how many doctors viewed a particular post, how many commented and how many voted on an associated poll question. An arrow will indicate if there is an increase in activity on companies or topics that a client tracks.

"It is useful because we are alerted when new comments are posted on a company we cover," stated the director of independent research at a large mutual fund who has been a client of Sermo for six months.

Perhaps the most valuable tool is that clients are able to create and post specific questions to doctors. Typically after a day or two, they will receive 40 comments, Palestrant said. After a week, there are typically as many as 200 comments.

"I'm on the website twice a day every day," the mutual fund research director said. There is immense value to be derived from the site, as there is no other way to reach a mass number of doctors so quickly, she said. "I don't have to take the time to call doctors or schedule interviews now," she said.

"After stress testing the system, as long as a question is well structured and you weed out what doctors you don't want responding to the question, companies can gain useful information," she said. Analysts sift through the data and then forward reports to the firm's portfolio managers, she said.

The system is not without some challenges, however. Sermo needs to understand what investors want most and how to set up a valuable screen on the front end, she said. The biggest challenge may be that there is so much data, and some of the information is not relevant to what you want or need at all, she said.

Compliance officers at firms are watchful of Sermo, Palestrant acknowledged. Compliance officers find research difficult to manage and audit, he said, but when working with Sermo, everything is in writing and easily trackable. There are no conflicts with the system and it is completely legal, he said.

"It is simply asking a group of physicians how an issue might turn out," he said. What would be illegal is if clients were specifically soliciting physicians involved in a clinical trial or study, and that is not happening, he said.

Palestrant is not launching any major advertising campaign, saying, "Wall Street is driven by the best and fastest services." Companies will learn about Sermo by word of mouth, he said.

While the concept of Sermo is transferable to other industries such as fashion, IT and real estate, Sermo is only focusing on healthcare, he said.

"Sermo is a great idea and would be valuable for analysts," said Susan Walton, director of international research at Integrity Research Associates of New York, adding that the service is probably cheaper than other expert matching companies.

Wall Street firms are not the only clients of Sermo.

Recently, the American Medical Association partnered with Sermo to tap into doctors' collective wisdom and better serve its members. The two-year deal allows the Chicago-based AMA to survey Sermo's members on hot topics, just as Sermo's Wall Street subscribers solicit doctors' opinions to help guide trading decisions on drug company and medical device stocks.

(c) 2007 Money Management Executive and SourceMedia, Inc. All Rights Reserved.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.